Replies to post #222216 on Biotech Values

[n4807g]

For me the confusion stems from how the NIH defines the condition. As defined NASH is a type of NAFLD. In the VKTX trial was the patient population defined beyond NAFLD? If the population was further defined as the other common form of, Simple fatty liver, I would agree the trials are not comparable.

It's also confusing because the press constantly compares the two drugs.